Translational Oncogenomic Laboratory

Vai ai contenuti


Publications in the last 5 years:
1. Puca R, Nardinocchi L, Gal H, Rechavi G, Amariglio N, Domany E, Notterman DA,
Scarsella M, Leonetti C, Sacchi A, Blandino G., Givol D, D'Orazi G. Reversible
dysfunction of wild-type p53 following homeodomain-interacting protein kinase-2
knockdown. Cancer Res. May 15;68(10):3707-14, 2008

2. Bossi G, Marampon F, Maor-Aloni R, Zani B, Rotter V, Oren M, Strano S, Blandino G.,
Sacchi A. Conditional RNA interference in vivo to study mutant p53 oncogenic gain of
function on tumor malignancy. Cell Cycle. 2008 Jun 15;7(12):1870-9. Epub Jun 16,

3. Di Agostino S, Cortese G, Monti O, Dell'Orso S, Sacchi A, Eisenstein M, Citro G,
Strano S, Blandino G. The disruption of the protein complex mutantp53/p73 increases
selectively the response of tumor cells to anticancer drugs. Cell Cycle. 2008 Nov
1;7(21):3440-7. Epub Nov 16, 2008

4. Blandino G. Mitosis poisons p53. Cell Cycle. Nov 1;7(21), 2008

5. Lapi E, Di Agostino S, Donzelli S, Gal H, Domany E, Rechavi G, Pandolfi PP, Givol D,
Strano S, Lu X, Blandino G. PML, YAP, and p73 are components of a proapoptotic
autoregulatory feedback loop. Mol Cell. Dec 26;32(6):803-14, 2008

6. Donzelli S, Biagioni F, Fausti F, Strano S, Fontemaggi G, Blandino G. Oncogenomic
Approaches in Exploring Gain of Function of Mutant p53. Curr Genomics.
May;9(3):200-7, 2008

7. Benassi B, Strano S, Blandino G. Tetraploidy triggers mitochondria. Cell Cycle. May
1;8(9):1305-6, 2009

8. Blandino G, Moll UM. p63 regulation by microRNAs. Cell Cycle. May 5;8(10):1466-7.
Epub 2009 May 15, 2009

9. Haupt S, Di Agostino S, Mizrahi I, Alsheich-Bartok O, Voorhoeve M, Damalas A,
Blandino G, Haupt Y. Promyelocytic leukemia protein is required for gain of function
by mutant p53. Cancer Res. Jun 1;69(11):4818-26, 2009

10. Bertini E, Oka T, Sudol M, Strano S, Blandino G. YAP: at the crossroad between
transformation and tumor suppression. Cell Cycle. 2009 Jan 1;8(1):49-57. Epub Jan
24, 2009

11. Bon G, Di Carlo SE, Folgiero V, Avetrani P, Lazzari C, D'Orazi G, Brizzi MF, Sacchi A,
Soddu S, Blandino G, Mottolese M, Falcioni R. Negative regulation of beta4 integrin
transcription by homeodomain-interacting protein kinase 2 and p53 impairs tumor
progression. Cancer Res. 2009 Jul 15;69(14):5978-86. Epub Jun 30, 2009

12. Muti P, Berrino F, Krogh V, Villarini A, Barba M, Strano S, Blandino G. Metformin, diet
and breast cancer: an avenue for chemoprevention. Cell Cycle. Aug 15;8(16):2661.
EpubAug 8, 2009

13. Careccia S, Mainardi S, Pelosi A, Gurtner A, Diverio D, Riccioni R, Testa U, Pelosi E,
Piaggio G, Sacchi A, Lavorgna S, Lo-Coco F, Blandino G., Levrero M, Rizzo MG. A
restricted signature of miRNAs distinguishes APL blasts from normal promyelocytes.
Oncogene. 2009 Nov 12;28(45):4034-40. Epub Sep 14, 2009

14. Fontemaggi G, Dell'Orso S, Trisciuoglio D, Shay T, Melucci E, Fazi F, Terrenato I,
Mottolese M, Muti P, Domany E, Del Bufalo D, Strano S, Blandino G. The execution of
the transcriptional axis mutant p53, E2F1 and ID4 promotes tumor neo-angiogenesis.
Nat Struct Mol Biol. 2009 Oct;16(10):1086-93. Epub Sep 27, 2009

15. Muscolini M, Montagni E, Caristi S, Nomura T, Kamada R, Di Agostino S, Corazzari M,
Piacentini M, Blandino G., Costanzo A, Sakaguchi K, Tuosto L. Characterization of a
new cancer-associated mutant of p53 with a missense mutation (K351N) in the
tetramerization domain. Cell Cycle. Oct 15;8(20):3396-405. Epub 2009 Oct 24, 2009

16. Barba M, Yang L, Schünemann HJ, Sperati F, Grioni S, Stranges S, Westerlind KC,
Blandino G, Gallucci M, Lauria R, Malorni L, Muti P. Urinary estrogen metabolites and
prostate cancer: a case-control study and meta-analysis. J Exp Clin Cancer Res. Oct
8;28:135, 2009

17. Blandino G, Shaul Y, Strano S, Sudol M, Yaffe M. The Hippo tumor suppressor
pathway: a brainstorming workshop. Sci Signal. 2009 Nov 3;2(95):mr6, 2009

18. Stambolsky P, Tabach Y, Fontemaggi G, Weisz L, Maor-Aloni R, Sigfried Z, Shiff I,
Kogan I, Shay M, Kalo E, Blandino G, Simon I, Oren M, Rotter V. Modulation of the
vitamin D3 response by cancer-associated mutant p53. Cancer Cell. Mar 16;17(3):273-
85, 2010

19. Avraham R, Sas-Chen A, Manor O, Steinfeld I, Shalg Ri, Tarcic G, Bossel N, Zeisel A,
Amit I, Enerly E, Russnes HG, Biagioni F, Mottolese M, Strano, Blandino G,
Børresen-Dale A, Pilpel Y, Yakhini Z, Segal E and Yarden Y. EGF Decreases the
abundance of microRNAs that restrain oncogenic transcription factors. Sci. Signal. Jun
1;3(124):ra43, 2010

20. Cioce M, Gherardi S, Viglietto G, Strano S, Blandino G, Muti P and Ciliberto G.
Enriched mammosphere-forming cells from breast cancer cell lines as a tool for the
identification of CSC-like targeting drugs. Cell Cycle, 2010 Jul 15;9(14):2878-87. Epub
Jul 13, 2010

21. Bruno T, Desantis A, Bossi G, Di Agostino S, Sorino C, De Nicola F, Iezzi S, Franchitto
A, Benassi B, Floridi A, Passananti C, Blandino G, and Fanciulli M. Che-1 depletion
inhibits mutant p53 expression and activates p73-dependent apoptsosis by inducing
endogenous DNA damage in human breast cancer. Cancer Cell, 2010 Aug

22. Slee E, Benassi B, Goldin R, Zhong S, Blandino G, and Lu X. Phosphorylation of
Ser312 contributes to tumour suppression by p53 in vivo. Proc Natl Acad Sci U S A.
2010 Nov 9;107(45):19479-84. Epub Oct 20, 2010 (IF: 9.771)

23. Santoro R, Blandino G. p53: The pivot between cell cycle arrest and senescence. Cell
Cycle, 2010 Nov;9(21):4262-3. Epub Nov 1, 2010

24. Fontemaggi G, Dell’Orso S, Muti P, Blandino G and Strano S. Id2 gene is a
transcriptional target of the protein complex mutant p53/E2F1. Cell Cycle 2010 Jun
15;9(12):2464-6. Epub Jun 15, 2010

25. Strano S and Blandino G. Stability strengths oncogenic activity. Cell Cycle 2010 Apr
15;9(8):1458-9. Epub Apr 15, 2010

26. Goeman F, Blandino G. Novel insights into the cytoplasmic functions of p53. Cell
Cycle. Jul 1;9(13):2498, 2010

27. Dell’Orso S, Ganci F, Strano S, Blandino G, and Fontemaggi G. ID-4: a new player in
the cancer arena. Oncotarget. May;1(1):48-58, 2010

28. Dell’Orso S, Fontemaggi G, Stambolsky P, Goeman F, Voellenkle C, Damalas A,
Levrero M, Strano S, Rotter V, Oren M and Blandino G. ChIP on chip analysis of in
vivo mutantp53 binding to selected gene promoters. OMICS. 2011 May;15(5):305-12.
Epub Feb 19, 2011

29. Muti P, Benassi B, Falvo E, Santoro R, Galanti S, Citro G, Carrubba G, Blandino G,
and Strano S. Omics underpins novel clues on VDR chemoprevention target in breast
cancer. OMICS. 2011 Jun;15(6):337-46. Epub Feb 24, 2011

30. Ganci F, Conti S, Fontemaggi G, Manciocco V, Donzelli S, Covello R, Muti P, Strano S,
Blandino G, Spriano G. Allelic expression imbalance of TP53 mutated and
polymorphic alleles in head and neck tumors. OMICS. 2011 Jun;15(6):375-81. Epub
Feb 24, 2011

31. Testoni B, Guerrieri F, Gerbal-Choine S, Blandino G and Levrero M. p53-paralog
DNp73 oncogene is repressed by IFNa/STAT2 through the recruitment of the Ezh2
Polycomb Group transcriptional repressor. Oncogene. 2011 Jun 9;30(23):2670-8. doi:
10.1038/onc.2010.635. Epub Mar 14, 2011 (IF: 7.414)

32. Sieri S, Muti P, Agnoli C, Berrino F, Pala V, Grioni S, Abagnato CA, Blandino G,
Contiero P, Schunemann H, Krogh V. Prospective study on the role of glucose
metabolism in breast cancer occurrence. Int J Cancer. 2011 Mar 16. doi:
10.1002/ijc.26071, 2011 (Epub ahead of print)

33. Testoni B, Voellenke C, Guerrieri F, Gerbal-Chaloin S, Blandino G, Levrero M.
Chromatin dynamics of gene activation and repression in response to ifn{alpha} reveal
new roles for phosphorylated and unphosphorylated forms of the transcription factor
STAT2. J Biol Chem. 2011 Jun 10;286(23):20217-27. Epub Apr 15, 2011

34. McNeill H, Sudol M, Halder G, Strano S, Blandino G, Shaul Y.Meeting Report The
Hippo tumor suppressor pathway: a report on the Second Workshop on the Hippo
tumor suppressor pathway’. Cell Death and Differentiation. Cell Death Differ. 2011
Aug;18(8):1388-90. doi: 10.1038/cdd.2011.61. Epub May 13, 2011

35. Di Agostino S, Strano S and Blandino G. YAP in Atlas Genetics. Oncology 2010 (in

36. Muscolini M, Montagni E, Palermo V, Di Agostino S, Gu W, Abdelmoula-Soussi S,
Mazzoni C, Blandino G and Tuosto L. The cancer-associated K351N mutation affects
the ubiquitination and the translocation to mitochondria of p53 protein. J. Biol. Chem.
Sept 27, asdoi:10.1074/jbc.M111.279539, 2011 (Epub ahead of print)

37. Botti E, Spallone G, Moretti F, Marinari B, Pinetti V, Galanti S, De Meo PD, De Nicola
F, Ganci F, Castrignanò T, pesole G, Chimenti S, Guerrini L, Fanciulli M, Blandino G,
Karin M, Costanzo A. Developmental factor IRF6 exhibits tumor suppressor activity in
squamous cell carcinomas. Proc Natl Acad Sci U S A. Aug 16;108(33):13710-5. Epub
Aug 1, 2011

38. Falvo E, Strigari L, Citro G, Giordano C, Arcangeli S, Soriani A, D’Alessia D, Muti P,
Blandino G, Sperduti I, Pinnarò P. Dose and polymorphic genes xrcc1, xrcc3, gst paly
a role in the risk of article developing erythema in breast cancer patients following
single shot partial breast irradiation after conservative surgery. BMC Cancer. Jul
12;11:291, 2011

39. Santoro R, Marani M, Blandino G, Muti P, Strano S. Melatonin triggers p53Ser
phosphorylation and prevents DNA damage accumulation. Oncogene Oct 17. doi:
10.1038/onc.2011.469, 2011(Epub ahead of print)

40. Blandino G, Deppert W, Hainaut P, Levine A, Lozano G, Olivier M, Rotter V, Wiman K
and Oren M. Mutant p53 protein, master regulator of human malignancies: a report on
the fifth Mutant p53 Workshop. Cell Death & Differentiation (in press)

41. Canino C, Mori F, Cambria A, Diamantini A, Germoni S, Alessandrini G, Borsellino G,
Galati R, Battistini L, Blandino R, Facciolo F, Citro G, Strano S, Muti P, Blandino G*,
Cioce M. SASP mediates chemoresistance and tumor-initiating-activity of
Mesothelioma cells. Oncogene Oct 24. doi: 10.1038/onc.2011.485, 2011 (Epub ahead
of print) (IF: 7.414) *corresponding author

42. Cioce M, Canino C, Muti P, Strano S, Blandino G. Butein impairs the pro-tumorigenic
activity of malignant pleural mesothelioma cells. Cell Cycle. Jan 1;11(1):132-40, 2012

43. Benassi B, Flavin R, Marchionni L, PanY, Chowdhury D, Marani M, Strano S, Muti P,
Blandino G*, and Loda M. c-Myc is activated via USP2a-mediated modulation of
microRNAs in prostate cancer. Cancer Discov. 2012 Mar;2(3):236-247 *cocorresponding

44. Cioce M, Blandino G. PGC1a Confers Specificity - Metabolic Stress and p53-
Dependent Transcription. Molecular Cell. Nov 18;44(4):515-6, 2011 (IF: 14.194)

45. Donzelli S, Fontemaggi G, Fazi F, Di Agostino S, Padula F, Biagioni F, Muti P, Strano
S, Blandino G. microRNA-128-2 targets the transcriptional repressor E2F5 enhancing
mutant p53 gain of function. Cell Death and Differentiation Jun;19(6):1038-48, 2012

46. Valenti F, Fausti F, Biagioni F, Fontemaggi G, Shay T, Domany E, Yaffe MB, Strano S,
Blandino G, Di Agostino S. Mutant p53 oncogenic functions are sustained by plk2
kinase through an autoregulatory feedback loop. Cell Cycle. Dec 15;10(24):4330-40,
2012 *co-corresponding author

47. Ciuffreda L, Di Sanza C, Cesta Incani U, Eramo A, Desideri M, Biagioni F, Passeri D,
Bergamo P, Anichini A, Sabapathy K, McCubrey J, Ricciardi MR, Tafuri A, Blandino G,
Orlandi A, Cognetti F, De Maria R, Del Bufalo D, Milella M. The mitogen activated
protein kinase (MARK) cascade controls phosphatase and tensin homolog (PTEN)
expression through multiple mechanisms. Journal of Molecular Medicine. Jan 4, 2012

48. Falvo E, Strigari L, Citro G, Giordano C, Boboc G, Fabretti F, Bruzzaniti V, Bellesi L,
Muti P, Blandino G, Pinnarò P SNPs in DNA repair or Oxidative Stress Genes and
Late Subcutaneous Fibrosis in Patients following a Single Shot Partial Breast
Irradiation. JECCR. Jan 24;31:7, 2012

49. Blandino G*1, Valerio M*, Cioce M*, Mori F, Casadei L, Pulito C, Sacconi A, Biagioni
F, Cortese G, Galanti S, Manetti C, Gennaro Citro G, Muti P, Strano S. Metformin
elicits anticancer effects through the sequential modulation of DICER, microRNAs and
c-MYC. Nat Commun 2012 may 29; 3:865 doi:10.1038/ncomms1859 1corresponding author

50. Cordelli, E; Eleuteri, P; Grollino, M; Benassi, B; Blandino, G; Bartoleschi, C; Pardini,
M; Di Caprio, E; Spanò, M; Pacchierotti, F; Villani, P. Direct and delayed X-ray induced
DNA damage in male mouse germ cells. Environmental and Molecular Mutagenesis

51. Biagioni F, Bossel Ben-Moshe N, Fontemaggi G, Canu V, Mori F, Antoniani B, Di
Benedetto A, Santoro R, Germoni S, De Angelis F, Cambria A, Avraham R, Grasso G,
Strano S, Muti P, Mottolese M, Yarden Y, Domany E and Blandino G. miR-10b*, a
master inhibitor of the cell cycle, is downregulated in human breast tumors. EMBO
Molecular Medicine Nov;4(11):1214-29

52. Sacconi A, Biagioni F, Canu V, Mori F, Di Benedetto A, Lorenzon L, Di Agostino S,
Cambria A.M., Germoni S, Grasso G, Blandino R, Panebianco V, Ziparo V, Federici O,
Muti P, Strano S, Carboni F, Mottolese M, Diodoro M, Pescarmona E, Garofalo A and
Blandino G. miR-204 targets Bcl-2 expression and enhances responsiveness of
gastric cancer. Cell Death and Disease 2012 Nov 15;3:e423

53. Fausti F, Di Agostino S, Sacconi A, Strano S, Blandino G. Hippo and rassf1a Pathways:
A Growing Affair. Mol Biol Int. 2012;2012:307628 1.

54. Santoro R, Marani M, Blandino G, Muti P, Strano S. Blockage of melatonin receptors impairs
p53-mediated prevention of DNA damage accumulation. Carcinogenesis, published online 25th Jan 2013.

55. Strano S, Fausti F, Di Agostino S, Sudol M, Blandino G. PML Surfs into HIPPO Tumor Suppressor
Pathway. Front Oncol. 2013;3:36. doi: 10.3389/fonc.2013.00036. Epub 2013 Mar 1.

56. Masciarelli S, Fontemaggi G, Di Agostino S, Donzelli S, Carcarino E, Strano S, Blandino
G. Gain-of-function mutant p53 downregulates miR-223 contributing to chemoresistance of
cultured tumor cells. Oncogene. 2013 Apr 15. doi: 10.1038/onc.2013.106.

57. Di Agostino S, Strano S, Blandino G. Gender
mutant p53 and PML: A growing "affaire" in tumor suppression and oncogenesis.
Cell Cycle. 2013 Jun 15;12(12):1824-5. doi: 10.4161/cc.25174. Epub 2013 Jun 5.

58. Mori F, Strano S, Blandino G.
MicroRNA-181a/b: Novel biomarkers to stratify breast cancer patients for PARPi treatment.
Cell Cycle. 2013 Jun 15;12(12):1823. doi: 10.4161/cc.25173. Epub 2013 May 30.

59. Schernhammer ES, Sperati F, Razavi P, Agnoli C, Sieri S, Berrino F, Krogh V, Abbagnato CA,
Grioni S, Blandino G, Schunemann HJ, Muti P. Endogenous sex steroids in premenopausal women
and risk of breast cancer: the ORDET cohort. Breast Cancer Res. 2013 Jun 18;15(3):R46.

60. Biagioni F, Bossel Ben-Moshe N, Fontemaggi G, Yarden Y, Domany E, Blandino G.
The locus of microRNA-10b: A critical target for breast cancer insurgence and dissemination.
Cell Cycle. 2013 Jun 26;12(15).

Home Page | Research | Publications | Meet the Lab | Grants | Collaborations | Contact | Links | Events | Mappa del sito

Torna ai contenuti | Torna al menu